|
⚲
|
| Keyboard |
| New Leaf Venture Partners LLC
✚
|
|
|---|---|
| CRD # | 163897 |
| SEC # | 801-80793 |
| CIK # | 0001375661, 0001441439, 0001455617, 0001441858, 0001625696, 0001455597, 0001625656, 0001416362, 0001441857, 0001631614 |
| AUM | 408.4 M (2026-03-30) |
| Employees | 4 (50% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 646-871-6420 |
| Address | 156 Fifth Avenue New York, NY 10010 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] |
| Total AUM ($M) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Edgewise Therapeutics Inc | 16.7 | ||
| Arvinas Inc | 13.5 | ||
| Crinetics Pharmaceuticals Inc | 5.9 | ||
| UNUM Therapeutics Inc | 3.6 | ||
| Rallybio Corp | 1.6 | ||
| Alector Inc | 1.0 | ||
| Passage Bio Inc | 0.7 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | NLV Co-Invest IV LP | [2025-03-31] | 16.7 M | 16.8 M |
| Offered $16,660,000 · Filed 2024-12-31 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| VC | NLV-II SPV-1 LP | [2024-03-28] | 90.8 M | |
| VC | NLV-II SPV-2 LP | [2024-03-28] | 9.0 M | |
| Filed 2023-11-13 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable | ||||
| VC | NLV Co-Invest III LLC | 2022-03-30 | 9.0 M | |
| VC | NLV Co-Invest II LLC | 2021-03-25 | 5.3 M | |
| VC | New Leaf Biopharma Opportunities II LP | [2019-03-29] | 120.7 M | |
| Offered $200,000,000 · Filed 2018-04-16 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $200,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | New Leaf Ventures IV LP | [2019-03-29] | 94.4 M | |
| Offered $275,000,000 · Filed 2018-04-16 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $275,000,000 · Duration One year or less · Finder's Fee $25,000 · Revenue Not Applicable | ||||
| VC | New Leaf Biopharma Opportunities I LP | [2014-12-19] | 10.0 M | |
| Offered $200,000,000 · Filed 2014-12-04 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $200,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | New Leaf Ventures III LP | [2014-12-19] | 62.4 M | |
| Offered $375,000,000 · Filed 2014-12-03 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $375,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | NLV Partners Co-Invest I LLC | 2014-12-19 | 8.0 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 9 | 408.4 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 9 | 408.4 |
| By Discretionary | ||
| Discretionary | 9 | 408.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 9 | 408.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 408.4 | |
| Total | 9 | 408.4 |
| Limited Partners | 2011 - 2026 |
|---|---|
| State of Michigan Retirement System |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Vijay Lathi | Executive Officer | 34 | 2 | |
| Jeani Delagardelle | Executive Officer | 32 | 2 | |
| Liam Ratcliffe | Executive Officer | 25 | 2 | |
| Ronald Hunt | Executive Officer | 25 | 2 | |
| Ron Hunt | Executive Officer | 19 | 2 | |
| Philippe Chambon | Executive Officer | 13 | 2 | |
| Isaac Manke | Executive Officer | 8 | 2 | |
| Nlv SPV GP LLC | Executive Officer | 3 | 2 | |
| New Leaf Venture Management III LLC | Director | 3 | 2 | |
| Craig Slutzkin | Executive Officer | 3 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001375661] | |
| 4 | [0001375661] | |
| SC 13G | [0001375661] | |
| 3 | [0001441439] | |
| 4 | [0001441439] | |
| SC 13D | [0001441439] | |
| SC 13G | [0001441439] | |
| 3 | [0001441857] | |
| 4 | [0001441857] | |
| 3 | [0001441858] | |
| 4 | [0001441858] | |
| 3 | [0001455597] | |
| 4 | [0001455597] | |
| 3 | [0001455617] | |
| 4 | [0001455617] | |
| 3 | [0001625656] | |
| 4 | [0001625656] | |
| 3 | [0001625696] | |
| 4 | [0001625696] | |
| D | [0001625696] | |
| SC 13G | [0001625696] | |
| 13F-HR | [0001631614] | |
| 3 | [0001631614] | |
| 4 | [0001631614] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Harpoon Therapeutics Inc HARP
Common Stock Warrant (Right to Buy) · derivative
|
2024-03-11 | Disposed to issuer | 299,430 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock
|
2024-03-11 | Disposed to issuer | 1,463,386 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock Warrant (Right to Buy) · derivative
|
2024-03-11 | Disposed to issuer | 686,000 | ||
|
Harpoon Therapeutics Inc HARP
8.000% Series A Redeemable Preferred Stock
|
2024-03-11 | Disposed to issuer | 10,000 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock Warrant (Right to Buy) · derivative
|
2024-03-11 | Disposed to issuer | 85,750 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock
|
2024-03-11 | Disposed to issuer | 395,783 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock Warrant (Right to Buy) · derivative
|
2023-10-25 | Buy | 686,000 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock
|
2023-10-25 | Buy | 1,372,000 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock
|
2023-10-25 | Buy | 171,500 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock Warrant (Right to Buy) · derivative
|
2023-10-25 | Buy | 85,750 | ||
|
Harpoon Therapeutics Inc HARP
Common Stock
|
2021-01-11 | Buy | 235,294 | $17.00 | 3,999,998 |
|
Deciphera Pharmaceuticals Inc DCPH
Common Stock
|
2019-08-16 | Sell | 26,108 | $37.01 | 966,257 |
|
Deciphera Pharmaceuticals Inc DCPH
Common Stock
|
2019-08-16 | Sell | 69,292 | $36.54 | 2,531,930 |
|
Deciphera Pharmaceuticals Inc DCPH
Common Stock
|
2019-08-16 | Sell | 28,626 | $37.01 | 1,059,448 |
|
Deciphera Pharmaceuticals Inc DCPH
Common Stock
|
2019-08-16 | Sell | 75,974 | $36.54 | 2,776,090 |
|
Deciphera Pharmaceuticals Inc DCPH
Common Stock
|
2019-08-15 | Sell | 71,550 | $36.09 | 2,582,240 |
|
Deciphera Pharmaceuticals Inc DCPH
Common Stock
|
2019-08-15 | Sell | 78,450 | $36.09 | 2,831,261 |
|
Principia Biopharma Inc PRNB
Common Stock
|
2019-08-13 | Sell | 49,991 | $35.00 | 1,749,685 |
|
Principia Biopharma Inc PRNB
Common Stock
|
2019-08-13 | Sell | 250,009 | $35.00 | 8,750,315 |
|
Harpoon Therapeutics Inc HARP
Common Stock
|
2019-02-12 | Buy | 214,285 | $14.00 | 2,999,990 |
| showing 20 of 131 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Auldbrass Partners LP
✚
|
NY | 412.9 M |
|
Auxo Investment Partners LLC
✚
|
MI | 412.0 M |
|
Vortus Investment Advisors LLC
✚
|
TX | 411.7 M |
|
Peloton Equity LLC
✚
|
CT | 409.5 M |
|
Greenridge Equity Partners LLC
✚
|
TX | 408.8 M |
|
Bridge Growth Partners LLC
✚
|
NY | 407.0 M |
|
Generation Partners Management LLC
✚
|
401.6 M | |
|
ROG IX LLC
✚
|
TX | 401.0 M |
|
Palm Peak Capital LLC
✚
|
FL | 400.8 M |
|
ValueQuest Advisers LLC
✚
|
NY | 400.8 M |